The demo realized the two its Key endpoints, with semaglutide two.4 mg demonstrating statistically important and top-quality advancements in liver fibrosis without having worsening of steatohepatitis, along with resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH when compared to placebo.oneNotify your doctor Fo